Skip to main content

Recognition and Management of Toxic Erythema of Chemotherapy for the Inpatient Dermatologist

Abstract

Purpose of Review

Toxic erythema of chemotherapy is an umbrella term for several non-allergic cutaneous reactions to chemotherapeutic agents. Given the heterogenous range of presentations, we will review the differential diagnoses and treatment approaches, particularly for hospitalized patients.

Recent Findings

Early recognition, holding chemotherapy, or dose reduction and monitoring fluid balance for severely ill patients is the mainstay of treatment. Supportive care with topical steroids, emollients, and wound care have shown benefit.

Summary

Toxic erythema of chemotherapy can mimic several common eruptions seen in oncologic patients. The recognition of both clinical and pathological features by inpatient dermatologists allows for appropriate management, and dose reduction if necessary, in order for patients to continue oncologic treatment.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.

    PubMed  Article  Google Scholar 

  2. 2.

    Horn TD. Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol. 1997;133(7):905–6.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Martschick A, Sehouli J, Patzelt A, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 2009;29(6):2307–13.

    CAS  PubMed  Google Scholar 

  5. 5.

    •• Hunjan MK, Nowsheen S, Ramos-Rodriguez AJ, et al. Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2019;12(1):19–25. Retrospective analysis of 40 stem cell transplant patients with suspected toxic erythema of chemotherapy. Presented a clinical spectrum and histopathological examples of toxic erythema of chemotherapy, and summarized criteria necessary for diagnosis.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94.

    PubMed  Article  Google Scholar 

  7. 7.

    Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97(1):61–2.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Chidharla A, Kanderi T, Kasi A. Chemotherapy Acral Erythema. StatPearls. Treasure Island (FL)2021.

  9. 9.

    Rodríguez-Lomba E, Molina-López I, Suárez-Fernández R, Baniandrés-Rodríguez O. Periarticular thenar erythema and onycholysis syndrome: a manifestation of taxane-induced cutaneous toxicity. Actas Dermo-Sifiliográficas (English Edition). 2017;108(6):595–7.

    Article  Google Scholar 

  10. 10.

    Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003;26(5):435–6.

    PubMed  Article  Google Scholar 

  11. 11.

    Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol May-Jun. 2000;18(3):319–30.

    CAS  Article  Google Scholar 

  12. 12.

    Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep. 2016;2(6):476–81.

    PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Wolf R, Tuzun Y. Baboon syndrome and toxic erythema of chemotherapy: fold (intertriginous) dermatoses. Clin Dermatol Jul-Aug. 2015;33(4):462–5.

    Article  Google Scholar 

  14. 14.

    Prieto-Barrios M, Velasco-Tamariz V, Tous-Romero F, et al. Ara-C ears: an actual drug-induced reaction or a distinctive manifestation of a neutrophilic dermatosis? J Dtsch Dermatol Ges. 2018;16(2):214–6.

    PubMed  Article  Google Scholar 

  15. 15.

    Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. A practical approach to the diagnosis and treatment of adult erythroderma. Actas Dermosifiliogr. 2018;109(9):777–90.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92(1):37–46.

    PubMed  Article  Google Scholar 

  17. 17.

    Gill J, Dominguez AR. Cutaneous manifestations of chemotherapeutic drugs. Current Dermatology Reports. 2016/03/01 2016;5(1):58–69.

  18. 18.

    Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin. 2019;37(4):569–82.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Mann N, King T, Murphy R. Review of primary and secondary erythromelalgia. Clin Exp Dermatol. 2019;44(5):477–82.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Sehgal VN, Jain S. Acrodermatitis enteropathica. Clin Dermatol Nov-Dec. 2000;18(6):745–8.

    CAS  Article  Google Scholar 

  22. 22.

    Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol. 2004;43(1):1–5.

    PubMed  Article  Google Scholar 

  23. 23.

    Patel GK, Finlay AY. Staphylococcal scalded skin syndrome. Am J Clin Dermatol. 2003/03/01 2003;4(3):165–175.

  24. 24.

    Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martinez A. Sweet syndrome: a review and update. Actas Dermosifiliogr. 2016;107(5):369–78.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Martinez-Leborans L, Victoria-Martinez AM, Torregrosa-Calatayud JL, Alegre de Miquel V. Leukemia cutis: a report of 17 cases and a review of the literature. Actas Dermosifiliogr. Nov 2016;107(9):e65-e69.

  26. 26.

    Beer J, Rosenbach M. Grover disease associated with chemotherapy: review of potential pathophysiology, current treatments, and future directions. J Drugs Dermatol. 2020;19(11):1056–64.

    PubMed  Article  Google Scholar 

  27. 27.

    Gantz M, Butler D, Goldberg M, Ryu J, McCalmont T, Shinkai K. Atypical features and systemic associations in extensive cases of Grover disease: a systematic review. J Am Acad Dermatol. Nov 2017;77(5):952–957 e951.

  28. 28.

    Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: pathogenesis, sweet syndrome, neutrophilic eccrine hidradenitis, and Behcet disease. J Am Acad Dermatol. 2018;79(6):987–1006.

    PubMed  Article  Google Scholar 

  29. 29.

    Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. Dermatol Ther (Heidelb). 2016;6(2):185–206.

    Article  Google Scholar 

  30. 30.

    Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15(11):1227–37.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Ji YZ, Geng L, Qu HM, et al. Acute generalized exanthematous pustulosis induced by docetaxel. Int J Dermatol. 2011;50(6):763–5.

    PubMed  Article  Google Scholar 

  32. 32.

    Chiu A, Kohler S, McGuire J, Kimball AB. Cytarabine-induced acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2002;47(4):633–5.

    PubMed  Article  Google Scholar 

  33. 33.

    Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician. 2005;72(5):833–8.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    •• Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B. Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol. 2016;74(6):1029–40. Systemic review and expert consensus on management of dermatologic adverse events from cancer therapies

    PubMed  Article  PubMed Central  Google Scholar 

  35. 35.

    Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. Nov 2012;67(5):1025–1039.

  36. 36.

    Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med. 1999;170(6):348–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Martorell-Calatayud A, Sanmartin O, Botella-Estrada R, et al. Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features. J Am Acad Dermatol. 2011;64(6):1092–103.

    PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62(2):361–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. Aug 2014;71(2):203 e201–203 e212; quiz 215–206.

  40. 40.

    Cury-Martins J, Eris APM, Abdalla CMZ, Silva GB, Moura VPT, Sanches JA. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol. Mar - Apr 2020;95(2):221–237.

  41. 41.

    Yoshino Y, Ohtsuka M, Kawaguchi M, et al. The wound/burn guidelines - 6: Guidelines for the management of burns. J Dermatol. 2016;43(9):989–1010.

    PubMed  Article  Google Scholar 

  42. 42.

    Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. Oct 8 2008(4):CD002106.

  43. 43.

    Bittner EA, Shank E, Woodson L, Martyn JA. Acute and perioperative care of the burn-injured patient. Anesthesiology. 2015;122(2):448–64.

    PubMed  Article  Google Scholar 

  44. 44.

    Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer. 2004;100(6):1199–207.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44(6):781–90.

    Article  CAS  Google Scholar 

  46. 46.

    von Gruenigen V, Frasure H, Fusco N, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010;116(20):4735–43.

    Article  CAS  Google Scholar 

  47. 47.

    Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8(1):57–63.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4(6):1567–71.

    CAS  PubMed  Google Scholar 

  49. 49.

    Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585–93.

    PubMed  Google Scholar 

  50. 50.

    Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004;94(2):320–4.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008;108(2):332–5.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.

    PubMed  Article  Google Scholar 

  53. 53.

    Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.

    PubMed  Article  Google Scholar 

  54. 54.

    Templeton AJ, Ribi K, Surber C, et al. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 2014;23(3):244–9.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lida Zheng.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Hospital-Based Dermatology

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lee, N., Zheng, L. Recognition and Management of Toxic Erythema of Chemotherapy for the Inpatient Dermatologist. Curr Derm Rep (2021). https://doi.org/10.1007/s13671-021-00344-3

Download citation

Keywords

  • Chemotherapy
  • Oncodermatology
  • Hand-foot syndrome
  • Toxic erythema of chemotherapy